文献速递肿瘤 PET/CT核素与放射性配体治疗

FAP-RADS 1.0版在肺癌与尿路上皮癌FAPI成像结构化报告中的可靠性与实用性

Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma.
PubMed 文献 · J Nucl Med · 2026-05-01

本研究回顾性评估FAP-RADS 1.0版在肺癌和尿路上皮癌患者FAPI PET/CT报告中的可靠性与一致性,4名不同经验读者独立评估60例患者的PET/CT。结果显示多数评估类别具有中等至高度读者间一致性,基于靶病灶的评估和总体FAP-RADS评分内部一致性几乎完美。结论认为该框架是标准化报告的有力工具,但需进一步验证其在其他肿瘤和FAP靶向配体中的适用性。

要点

  • FAP-RADS 1.0版在肺癌和尿路上皮癌FAPI PET/CT报告中显示中等至高度读者间一致性。
  • 基于靶病灶的评估和总体FAP-RADS评分内部一致性几乎完美(Cronbach α分别为0.92和0.88)。
  • 基于示踪剂摄取强度和疾病范围推荐放射性药物治疗的读者间一致性高(κ分别为0.70和0.66)。

核心结论

  • FAP-RADS 1.0版框架在临床研究和常规实践中是标准化报告的有力工具,多数评估类别显示高度读者间一致性。
  • 需进一步研究验证其适用性于其他肿瘤实体和其他FAP靶向配体。

研究设计与样本

  • 回顾性研究,4名不同PET/CT经验读者(2名>10年、1名6年、1名<3年住院医师)在不知晓临床信息情况下独立评估60例患者(30例肺癌、30例尿路上皮癌)的PET/CT。
  • 每例最多识别5个靶病灶,每个器官或区域最多3个,最终总体FAP-RADS评分为所评估靶病灶中的最高分。

主要发现

  • 总体扫描印象和淋巴结转移存在的读者间一致性为中等至高度,κ值分别为0.62(95%CI 0.52-0.73)和0.59(95%CI 0.49-0.69)。
  • 基于示踪剂摄取强度和疾病范围推荐放射性药物治疗的读者间一致性高,κ值分别为0.70(95%CI 0.60-0.81)和0.66(95%CI 0.55-0.76)。
  • 靶病灶评估和总体FAP-RADS评分的内部一致性几乎完美,Cronbach α分别为0.92和0.88。
  • 靶病灶FAP-RADS评分在经验丰富和较少经验读者中均显示高度读者间一致性,加权κ值分别为0.72(95%CI 0.53-0.91)和0.75(95%CI 0.57-0.92)。

临床怎么用

  • FAP-RADS 1.0版可用于肺癌和尿路上皮癌患者FAPI PET/CT的结构化报告,促进标准化评估。
  • 该框架有助于统一靶病灶选择、总体评分及基于摄取强度和疾病范围的治疗推荐。

局限性

  • 需进一步研究验证该框架在其他肿瘤实体和其他FAP靶向配体中的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recently, a collaborative effort among research centers in the United States and Europe resulted in the development of fibroblast activation protein reporting and data system (FAP-RADS) version 1.0, a reporting framework for fibroblast activation protein (FAP)-targeted imaging using the fundamental principles of the molecular imaging reporting and data systems framework. This retrospective study aimed to investigate the reliability and consistency of FAP-RADS version 1.0 framework for patients with lung cancer and urothelial cancer. Methods: Four readers with varying levels of PET/CT experience, working without access to clinical patient information (2 readers with more than 10 y of experience, 1 reader with 6 y of experience, and a nuclear medicine resident with less than 3 y of experience) evaluated PET/CT scans from a total of 60 patients (30 with lung cancer and 30 with urothelial cancer). Readers were instructed to identify no more than 5 target lesions (TLs) per patient, with a maximum of 3 TLs per organ or compartment. Each evaluation required the assignment of a final overall FAP-RADS score, defined as the highest score among the assessed TLs. Results: Interreader agreement for the overall scan impression and the presence of lymph node metastases was moderate to substantial, with κ values of 0.62 (95% CI, 0.52-0.73) and 0.59 (95% CI, 0.49-0.69), respectively. Interreader agreement regarding referral for radiopharmaceutical therapy on the basis of tracer uptake intensity and disease extent were high, with κ values of 0.70 (95% CI, 0.60-0.81) and 0.66 (95% CI, 0.55-0.76), respectively. The internal consistency for TL-based assessments and overall FAP-RADS score was almost perfect, with a Cronbach α of 0.92 and 0.88, respectively. Analyses of TL-based FAP-RADS scores demonstrated high interreader agreement for both experienced and less experienced readers, with weighted κ values of 0.72 (95% CI, 0.53-0.91) and 0.75 (95% CI, 0.57-0.92), respectively. Conclusion: The FAP-RADS version 1.0 framework appears to be a robust tool for standardized reporting in both clinical studies and routine clinical practice, demonstrating substantial interreader agreement across most evaluated categories. Further studies are warranted to validate its applicability in additional tumor entities and with other FAP-targeting ligands.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Novruzov E, Mamlins E, Widjaja L, et al. Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma. J Nucl Med. 2026. PMID: 41714120. doi:10.2967/jnumed.125.271080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。